Humanin

Humanin is one of the more scientifically intriguing peptides in the “longevity” corner of the gray market. It was the first mitochondrial-derived peptide ever found, it has a believable way of protecting cells, and the amount of it in your blood goes down as you age. But here’s the catch: as of mid-2026, there is essentially no human evidence that injecting it does anything useful — or that it’s even safe. Everything exciting about humanin comes from lab dishes and animals, not people.

What it is

Humanin is a small peptide (a short chain of amino acids, the building blocks of proteins) just 24 amino acids long. Its sequence is MAPRGFSCLLLLTSEIDLPVKRRA. What makes it unusual is where its instructions live: not in your nuclear DNA (the main genome in the cell’s nucleus), but in a short stretch inside the mitochondrial 16S rRNA gene (MT-RNR2) — code that sits in the mitochondria, the tiny “power plants” inside your cells. It was the first known member of a small family of mitochondrial-derived peptides, a group that also includes MOTS-c.

Three labs stumbled onto it independently around 2001: the Nishimoto group (then at Keio University), who published first; the Reed lab, which found it while hunting for proteins that latch onto BAX; and the Pinchas Cohen lab, which found it through an IGFBP-3 interaction screen.

What does it actually do? Almost everything we know comes from cells and animals. The short version is that it helps cells survive. It interacts with the BCL-2 family of proteins (which help decide whether a cell lives or dies, notably BAX), it binds a protein called IGFBP-3, and it switches on several internal signaling pathways (it works through a three-part CNTFR/WSX-1/gp130 receptor to fire up JAK/STAT3, and also turns on ERK1/2 and Akt). In the lab (in vitro, meaning in cells in a dish), it reduces cell death caused by oxidative stress (damage from reactive molecules) and by starving cells of nutrients.

One practical wrinkle: natural humanin disappears from the bloodstream very quickly, so most animal research uses HNG (also called the S14G analog), a tweaked synthetic version that is more stable and far more potent (reported up to roughly 1000-fold stronger, depending on the test). And yes, the amount of humanin in people’s blood drops with age — but that’s just a correlation we can observe. It does not prove that topping it up helps anything.

The claims

Marketing and clinic copy pitch humanin as a longevity, neuroprotective (“brain-protecting”), and “cellular repair” peptide. You’ll see claims that it protects brain cells, slows mental aging, improves metabolic health, and extends your healthy years. The pitch leans on two real facts — that humanin protects cells in the lab, and that its levels drop as we age — and then makes a big leap: that injecting it will reverse or delay age-related decline in humans. That leap has not been tested.

What the evidence actually shows

The lab and animal signals are real and fairly consistent. The human data, though, are purely observational — meaning researchers only watched and measured, they never gave anyone humanin. In fact, no one in the published literature has ever received humanin as a drug.

• Cognitive aging (Yen et al., Scientific Reports 2018): The part where they actually gave the compound was done in mice — HNG injected into aged mice improved their thinking and behavior. The human part was just observation: a tiny genetic variant (a SNP, or single-letter change in DNA, called rs2854128) was linked to roughly 14% lower circulating humanin and to faster cognitive aging in the Health and Retirement Study group (about 20,000 US adults over 50; the effect stood out in African-American participants). No human was given humanin.
• Lifespan/healthspan (Yen et al., Aging 2020): Making more humanin extended lifespan in C. elegans (a tiny worm often used in aging research, via the daf-16/FOXO pathway), and treating mice in midlife improved metabolic measures, with supporting data across species from rhesus macaques and naked mole-rats. The human findings are correlations only — for example, the children of people who lived to 100 tended to have higher humanin. No human was treated.
• Cardiac (Qin et al., Am J Physiol Heart Circ Physiol 2018): Long-term HNG reduced age-related scarring (fibrosis) and cell death in heart muscle — but only in mice.
• Neuroprotection and amyloid toxicity: a solid body of work in cells and rodents (amyloid is the sticky protein that builds up in Alzheimer’s), but with no confirmation in humans.

There is no completed or published Phase 1, 2, or 3 trial of humanin or HNG given to people as a treatment (those numbered phases are the standard steps of testing a drug in humans), and no registered ClinicalTrials.gov study of giving humanin to people could be found. One point trips a lot of people up: a related but different mitochondrial-derived peptide called MOTS-c (a 16-amino-acid peptide from the 12S rRNA region) does show up in human observation and exercise studies, and a separate MOTS-c prediabetes trial is reportedly underway — but that’s MOTS-c, not humanin, and the two shouldn’t be mixed up. The mechanism is interesting and the animal signals line up, but the actual human evidence for humanin is basically nonexistent. Any longevity, brain-boosting, or recovery claim for injected humanin in people is not backed by human trials.

Legal and regulatory status

Humanin is not approved by the FDA or any comparable regulator for any use, and it is not a dietary supplement. Anything sold online is research-grade/gray-market — unapproved and unregulated, with no guarantee that what’s in the vial matches the label or is the right purity or dose.

On anti-doping: humanin is not listed by name on the WADA 2026 Prohibited List (WADA is the World Anti-Doping Agency). But “not named” does not mean “allowed.” The WADA List is deliberately non-exhaustive, so a substance can be banned by falling into a category even if it isn’t spelled out. WADA’s S2 class (Peptide Hormones, Growth Factors, Related Substances and Mimetics) is open-ended — it covers related substances and mimics with similar biological effects — and a cell-protecting signaling peptide marketed for performance or recovery could plausibly be argued into it. It could also fall under the S0 “Non-Approved Substances” catch-all, since humanin has no regulatory approval for human use. The 2026 List also newly added cell components, including organelles such as mitochondria and ribosomes (organelles are the small working parts inside cells), to the gene/cell-doping (M-class) ban. That provision is aimed at transferring cells and organelles rather than this peptide itself, but it shows WADA is paying closer attention to mitochondrial methods. (For reference, SARMs fall under S1.2 and metabolic modulators like AICAR under S4 — neither applies to humanin, which is a peptide.) Athletes should treat humanin as high-risk and likely prohibited under S0/S2, and get a formal ruling before going anywhere near it. Again: “not named” does not mean “allowed.”

Safety

Human safety is essentially a blank slate. No completed or published human safety study (a Phase 1 trial, the first step that checks safety in people) could be verified, so there is no controlled human safety data at any dose. When vendor or clinic copy claims a “favorable safety profile with no serious adverse events at clinical doses,” that statement contradicts itself — it can’t be true alongside the fact that no human trial exists — and it isn’t backed by any published human trial data. Ignore it.

Two more worries are worth spelling out. First, product-quality risk is real: research-grade and gray-market peptides often have genuine problems with purity, sterility, endotoxin contamination (toxins from bacteria that can cause fevers and reactions), and mislabeling — problems that have nothing to do with the molecule itself. Second, there’s a theoretical concern rooted in how it works: humanin’s main job is to keep cells alive and block their normal self-destruct program (apoptosis, or programmed cell death). Chronically dialing down that self-destruct program raises an unanswered question about whether the body can still catch and clear cancerous cells and keep tissues balanced — and there is no human safety monitoring to tell us whether this matters in practice. Long-term effects, interactions with other drugs, and effects on specific organs in humans are simply unknown. None of this is medical advice.

Bottom line

Humanin rests on a genuinely interesting foundation in biology — the first mitochondrial-derived peptide, a coherent cell-protecting mechanism, and consistent signals in cells and animals — but a nearly empty one in humans. Every human study so far is observational or correlational; no one has been given humanin in a trial, and its human safety is uncharacterized. It is an unapproved, research-grade compound that should be treated as high-risk in sport. Anyone using injected humanin as a proven longevity, brain, or recovery therapy is way out ahead of the evidence.

Evidence grade: 3/10 · Animal only.

Sources

• Hashimoto T, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. PNAS 2001;98(11):6336–41 (PMID: 11371646)
• Yen K, et al. Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans. Scientific Reports 2018;8:14212 (PMID: 30242290; PMC6154958)
• Qin Q, et al. Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice. Am J Physiol Heart Circ Physiol 2018;315(5):H1127–H1136 (PMID: 30004252; PMC6415743)
• Yen K, et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY) 2020;12(12):11185–11199 (DOI: 10.18632/aging.103534)
• Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives. Biology (Basel) 2023;12(12):1534 (PMC10740898)
• WADA 2026 Prohibited List — World Anti-Doping Agency
• USADA — What’s New on the 2026 WADA Prohibited List?